Separation of nanoparticles
US-2015375180-A1 · Dec 31, 2015 · US
Pyrroloquinolin compounds and methods of using same
US11020488B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11020488-B2 |
| Application number | US-201816493690-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2018 |
| Priority date | Mar 14, 2017 |
| Publication date | Jun 1, 2021 |
| Grant date | Jun 1, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 2. A pharmaceutical composition, comprising: the compound of claim 1 ; and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07D471/06Primary
Peri-condensed systems · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Antineoplastic agents · CPC title
- A61K47/6803Primary
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11020488B2 cover?
- Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the pres…
- Who is the assignee on this patent?
- Univ California, Ford Henry Health System
- What technology area does this patent fall under?
- Primary CPC classification C07D471/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).